Integrated manufacturing for gene editing therapeutics

With the acquisition of BIOVECTRA—a CDMO with deep expertise in complex biologics—Agilent now delivers a fully integrated workflow. From single-guide RNA (sgRNA) production to sterile fill/finish, this workflow streamlines gene editing therapeutic development, reducing complexity and accelerating timelines for both ex vivo and in vivo gene editing programs.